Governor Kemp Calls Special Session

June 4, 2026 - Governor Brian Kemp has issued a formal proclamation convening the Georgia General Assembly in a special session, signaling the need for legislative action outside the regular session calendar. Under the Georgia Constitution, the Governor is empowered to call a special session and define the scope of issues lawmakers may consider. In this instance, the proclamation outlines the specific subject matter to be addressed, effectively limiting legislative activity to those enumerated items.


The proclamation underscores the urgency and importance the administration places on the identified issues, which may include time-sensitive fiscal matters, policy priorities, or emergent statewide concerns that cannot reasonably wait until the next regular session. By setting the agenda, the Governor not only accelerates legislative consideration but also shapes the policy framework within which the General Assembly must operate.


From a practical standpoint, the special session compresses the legislative timeline, requiring stakeholders to quickly mobilize, engage decision-makers, and adapt strategies in a fast-moving environment. For clients and partners, this means heightened attention to committee activity, leadership negotiations, and potential amendments, as outcomes are often determined on an expedited basis.

 Topspin Strategies will continue to monitor developments closely, provide real-time updates, and engage with key policymakers to ensure our clients’ priorities are effectively represented throughout the duration of the special session.

 

Details About the Code Sections Being Discussed:

 

Code Section 21-2-379.23


This law applies to Georgia’s electronic ballot marking devices.


Key requirements:

  • Ballots must include standard info like:
  • “OFFICIAL BALLOT”
  • Election date
  • Candidates, offices, and questions
  • Ballots must be printed on secure paper with features like a watermark.

The text on the paper ballot is the official vote


  • The human-readable text (what you can read on the ballot)
    =
    the legally binding vote
  • This applies to:
  • Vote tabulation
  • Recounts
  • Audits


What S.B. 189 changed


The 2024 law (Act 697 / S.B. 189) made a major shift:

  • It prohibits relying on QR codes or machine-readable codes to count votes
  • Instead, only the printed text must be counted
  • The key changes to this section are scheduled to take effect July 1, 2026


This code section is at the center of current election debates because:

  • Georgia’s existing voting system relies on QR codes for tabulation
  • The law forces a transition to text-based counting
  • State and local officials have warned this creates:
  • Logistical challenges
  • Potential funding gaps
  • Uncertainty before elections

 

Code Section 48-8-109.52


This section (added by S.B. 33) deals with a specific type of local sales tax authority.


From the bill text, it ties to:

  • Local governments that levy certain property taxes (ad valorem taxes)
  • And allows or governs how they can adopt an additional local sales tax via local legislation
  • It creates a framework for certain local governments to pass a new or modified local sales tax, but they must do it through a local Act.
  • If a county/city wants to use this new tax authority
  • The legislature must pass a local bill (local Act) following the rules in that code section S.B. 33 (Act 461, 2026)


This is the law that:

  • Created or updated this tax mechanism
  • Set the rules + process for how locals can implement it
August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters
August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .
August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS